Equilis Te Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

equilis te

intervet international bv - tetanus toxoid - immunologicals for equidae - horses - active immunisation of horses from 6 months of age against tetanus to prevent mortality.onset of immunity: 2 weeks after the primary vaccination courseduration of immunity: 17 months after the primary vaccination course, 24 months after the first revaccination

RHODIOLA TABLETAS Պանամա - անգլերեն - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

rhodiola tabletas

access busines group llc - te verde (camellia sinensis, hojas) - te verde (camellia sinensis, hojas)....172.49 mg / rhodiola rosea (raiz)....105.00 mg / polvo de espinaca (spinacia oleracea, partes aereas: hojas y tallos)....52.50 mg / concentrado de cereza acerola (malphigia glabra, frutos)....31.61 mg / Ácido ascÓrbico....28.42 mg

Lenalidomide Te Arai Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

lenalidomide te arai

te arai biofarma limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: allura red ac brilliant blue fcf croscarmellose sodium erythrosine gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Lenalidomide Te Arai Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

lenalidomide te arai

te arai biofarma limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.